Victoza, a top-selling diabetes drug developed by Denmark-based pharmaceutical firm Novo Nordisk, has been increasingly associated with potentially adverse health risks among its users, according to online news reports. As a result, some medical experts from different medical communities have reportedly started to raise questions about the safety of the medication. These problems have also warranted the scrutiny of the United States Food and Drug Administration and a number of potential Victoza lawsuits from patients who claim of suffering from injuries from the drug.
Early this year, the US FDA warned the public that Victoza (liraglutide), as well as other incretin mimetics, may be potentially linked to serious health problems related to the pancreas, online sources say. The FDA indicated in a drug safety communication in March that this type of medications bears the propensity to cause pancreatitis or inflammation of the pancreas, and cellular changes that may lead to cancer. This was reportedly released following an unpublished study of medical researchers who analyzed samples of pancreatic tissues from patients whose cause of death was undetermined.
Incretin mimetics are a type of medications used to treat diabetes mellitus type 2 or type 2 diabetes — a metabolic disorder marked by increased blood sugar or glucose levels. Dubbed by many experts as wonder drugs for the said condition, incretin mimetics mimic the same incretin hormone known as glucagon-like peptide 1 (GLP-1), which play a vital role in producing more insulin in response to an increase in glucose. Insulin, on the other hand, lowers blood sugar levels by helping the body use glucose for energy. Other incretin mimetics widely distributed in the US also include Byetta by Amylin Pharmaceuticals and Januvia by Merck.
This was not the first time that Victoza has been hounded by controversies concerning its safety. In fact, Public Citizen, a consumer rights advocacy organization, has even disagreed with the FDA’s decision to approve the drug in January 2010. The Washington, DC-based group petitioned the government agency to take the product off the market, saying that it may put patients susceptible to an increased risk for adverse health problems, including kidney failure and even thyroid cancer, according to a Reuters report. Previously conducted studies have also revealed that pancreatitis occurred more often in patients who were prescribed with Victoza than those who used other similar drugs.
Nevertheless, the FDA came to the conclusion that the benefits of Victoza substantially outweigh its known risks. Despite that, numerous patients who may have been injured by the drug are reportedly contemplating on filing a lawsuit involving Victoza side effects. Added information related to safety issues concerning Victoza may also be found on various personal injury law firm sites, including the Rottenstein Law Group’s online information center found at www.rotlaw.com.
Early this year, the US FDA warned the public that Victoza (liraglutide), as well as other incretin mimetics, may be potentially linked to serious health problems related to the pancreas, online sources say. The FDA indicated in a drug safety communication in March that this type of medications bears the propensity to cause pancreatitis or inflammation of the pancreas, and cellular changes that may lead to cancer. This was reportedly released following an unpublished study of medical researchers who analyzed samples of pancreatic tissues from patients whose cause of death was undetermined.
Incretin mimetics are a type of medications used to treat diabetes mellitus type 2 or type 2 diabetes — a metabolic disorder marked by increased blood sugar or glucose levels. Dubbed by many experts as wonder drugs for the said condition, incretin mimetics mimic the same incretin hormone known as glucagon-like peptide 1 (GLP-1), which play a vital role in producing more insulin in response to an increase in glucose. Insulin, on the other hand, lowers blood sugar levels by helping the body use glucose for energy. Other incretin mimetics widely distributed in the US also include Byetta by Amylin Pharmaceuticals and Januvia by Merck.
This was not the first time that Victoza has been hounded by controversies concerning its safety. In fact, Public Citizen, a consumer rights advocacy organization, has even disagreed with the FDA’s decision to approve the drug in January 2010. The Washington, DC-based group petitioned the government agency to take the product off the market, saying that it may put patients susceptible to an increased risk for adverse health problems, including kidney failure and even thyroid cancer, according to a Reuters report. Previously conducted studies have also revealed that pancreatitis occurred more often in patients who were prescribed with Victoza than those who used other similar drugs.
Nevertheless, the FDA came to the conclusion that the benefits of Victoza substantially outweigh its known risks. Despite that, numerous patients who may have been injured by the drug are reportedly contemplating on filing a lawsuit involving Victoza side effects. Added information related to safety issues concerning Victoza may also be found on various personal injury law firm sites, including the Rottenstein Law Group’s online information center found at www.rotlaw.com.
No comments:
Post a Comment